BUZZ-Australia's Rhythm Biosciences set for best day in four months on commercialisation of cancer test

Reuters

Dec 12

BUZZ-Australia's <a href="https://laohu8.com/S/RHYN.AU">Rhythm Biosciences</a> set for best day in four months on commercialisation of cancer test

** Shares of Australia's Rhythm Biosciences RHY.AX jump 38.6% to A$0.115, set for best day since August 6 if gains hold

** Stock at highest since October 15

** Cancer diagnostics tech firm commences commercialisation of its flagship blood-based colorectal cancer test - ColoSTAT

** YTD shares up 32.2%

(Reporting by Shruti Agarwal in Bengaluru)

((Shruti.Agarwal@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590297875"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590297875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590297875?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 11:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590297875","market":"fut","top_or_hot":-1,"title":"BUZZ-Australia's Rhythm Biosciences set for best day in four months on commercialisation of cancer test","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> set for best day in four months on commercialisation of cancer test</title></head><body><p>** Shares of Australia's <a href=\"https://laohu8.com/S/RHYBF\">Rhythm Biosciences</a>  <span>RHY.AX</span> jump 38.6% to A$0.115, set for best day since August 6 if gains hold </p><p>** Stock at highest since October 15 </p><p>** Cancer diagnostics tech firm <span>commences</span> commercialisation of its flagship blood-based colorectal cancer test - ColoSTAT</p><p>** YTD shares up 32.2% </p><p> (Reporting by Shruti Agarwal in Bengaluru)</p><p> ((Shruti.Agarwal@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Rhythm Biosciences set for best day in four months on commercialisation of cancer test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Rhythm Biosciences set for best day in four months on commercialisation of cancer test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 11:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> set for best day in four months on commercialisation of cancer test</title></head><body><p>** Shares of Australia's <a href=\"https://laohu8.com/S/RHYBF\">Rhythm Biosciences</a>  <span>RHY.AX</span> jump 38.6% to A$0.115, set for best day since August 6 if gains hold </p><p>** Stock at highest since October 15 </p><p>** Cancer diagnostics tech firm <span>commences</span> commercialisation of its flagship blood-based colorectal cancer test - ColoSTAT</p><p>** YTD shares up 32.2% </p><p> (Reporting by Shruti Agarwal in Bengaluru)</p><p> ((Shruti.Agarwal@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHY.AU","symbol_name":"RHYTHM BIOSCIENCES LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL6N3XI05X:1","article_id":"2590297875","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590297875","pubTimestamp":1765508890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Rhythm Biosciences set for best day in four months on commercialisation of cancer test** Shares of Australia's Rhythm Biosciences  RHY.AX jump 38.6% to A$0.115, set for best day since August 6 if gains hold ** Stock at highest since October 15 ** Cancer diagnostics tech firm commences commercialisation of its flagship blood-based colorectal cancer test - ColoSTAT** YTD shares up 32.2%   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHY.AU":"RHYTHM BIOSCIENCES LTD","BK7124":"保健护理服务"},"translate_title":"BUZZ-澳大利亚Rhythm Biosciences癌症检测商业化创下四个月来最好的一天","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHY.AU":0.9},"content_text":"BUZZ-Australia's Rhythm Biosciences set for best day in four months on commercialisation of cancer test** Shares of Australia's Rhythm Biosciences RHY.AX jump 38.6% to A$0.115, set for best day since August 6 if gains hold ** Stock at highest since October 15 ** Cancer diagnostics tech firm commences commercialisation of its flagship blood-based colorectal cancer test - ColoSTAT** YTD shares up 32.2%  (Reporting by Shruti Agarwal in Bengaluru) ((Shruti.Agarwal@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}